02:41 , Mar 15, 2019 |  BC Innovations  |  Product Development

Fresh AIMMs for elite responders

AIMM Therapeutics B.V.’s elite responder platform has identified mAbs that distinguish tumor and healthy cells based on protein modifications. The company is one of a handful of players mining the immune systems of cancer patients...
20:08 , Dec 21, 2018 |  BC Week In Review  |  Financial News

RiverVest closes fourth life science venture fund

RiverVest Venture Partners announced the final close of RiverVest Venture Fund IV at $184.4 million. The firm has invested in eight companies from the fund to date, including cancer company OncoResponse Inc. (Houston, Texas) and...
21:04 , Dec 18, 2018 |  BC Extra  |  Financial News

RiverVest closes new fund at $184.4M

RiverVest Venture Partners announced the final close of RiverVest Venture Fund IV at $184.4 million. The firm has invested in eight companies from the fund to date, including cancer company OncoResponse Inc. (Houston, Texas) and...
17:25 , Sep 14, 2018 |  BC Week In Review  |  Financial News

OncoResponse to move into clinic with $40M series B

OncoResponse Inc. (Houston, Texas) raised $40 million in a series B round led by RiverVest Venture Partners. Fellow new investors Qatar Investment Authority and Redmile Group participated, as did existing investors Alexandria Venture Investments, Arch...
22:22 , Sep 11, 2018 |  BC Extra  |  Financial News

OncoResponse to move into clinic with $40M series B

OncoResponse Inc. (Houston, Texas) raised $40 million in a series B round led by RiverVest Venture Partners. Fellow new investors Qatar Investment Authority and Redmile Group participated, as did existing investors Alexandria Venture Investments, Arch...
23:54 , Jan 4, 2018 |  BC Extra  |  Company News

Management tracks: Acceleron, Selecta

Acceleron Pharma Inc. (NASDAQ:XLRN) said EVP and CMO Matthew Sherman will retire after the company reports top-line data mid-year from the Phase III MEDALIST and BELIEVE trials of luspatercept (ACE-536) to treat lower-risk myelodysplastic syndromes...
19:03 , Aug 17, 2017 |  BC Extra  |  Financial News

Atreca raises $35M in series B

Cancer immunotherapy company Atreca Inc. (Redwood City, Calif.) raised $35 million in a series B round co-led by new investor Wellington Management and an undisclosed U.S. healthcare fund, which is an existing investor. New investor...
19:50 , Mar 15, 2017 |  BC Week In Review  |  Financial News

OncoResponse completes venture financing

On March 9, OncoResponse Inc. (Houston, Texas) raised an undisclosed amount in the final close of a series A round, bringing the total raised to $22.5 million. The company discovers therapeutic antibodies against immuno-oncology targets....
07:00 , Oct 17, 2016 |  BioCentury  |  Finance

Helsinn looks upstream

Helsinn Investment Fund S.A. is primarily looking for financial returns, but the new early stage venture fund's investment remit also could lead to deals that would expand Helsinn Healthcare S.A.'s specialty pharma pipeline into new...
07:00 , Oct 17, 2016 |  BC Week In Review  |  Financial News

OncoResponse financial update

OncoResponse Inc. , Seattle, Wash.   Business: Cancer, Antibodies   Date announced: 2016-10-10   Note: OncoResponse raised $7 million in an extension of a series A round, bringing the total raised in the round to...